Latest Neuroendocrine tumor Stories
EAST HANOVER, N.J., May 5, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved AfinitorÂ® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease(4).
EAST HANOVER, N.J., April 12, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of AfinitorÂ® (everolimus) tablets for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin. The recommendation was provided after presentation of data from the everolimus RADIANT (RAD001 In Advanced Neuroendocrine Tumors) trial...
BERLIN, April 12, 2011 /PRNewswire/ -- OctreoPharm Sciences GmbH, a specialist for contrast media in Nuclear Medicine, was able to successfully close a financing round for the clinical development of its cancer diagnostic SOMscan(R).
SILVER SPRING, Md., April 11, 2011 /PRNewswire-USNewswire/ -- Science, public health, and regulatory highlights for this week from the U.S. Food and Drug Administration. Information in this document is designed for credentialed journalists.
Preliminary analysis shows treatment is well-tolerated and consistently delivered to patients with metastatic liver cancer OTTAWA, March 28 /PRNewswire-FirstCall/ - Nordion Inc.
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors (pNET), according to researchers from The University of Texas MD Anderson Cancer Center.
EAST HANOVER, N.J., Feb.
Scientists at Johns Hopkins have deciphered the genetic code for a type of pancreatic cancer, called neuroendocrine or islet cell tumors.
BERLIN, January 21, 2011 /PRNewswire-FirstCall/ -- Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a firm specializing in radioactive compounds for the treatment of cancer, has renewed the approval of its drug YTTRIGA (Yttrium-90 chloride) by the European Commission.
BOSTON, Jan. 20, 2011 /PRNewswire-USNewswire/ -- Through a grant provided by the Caring for Carcinoid Foundation (www.caringforcarcinoid.org), researchers at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center have discovered several key mutations in pancreatic neuroendocrine tumors.
- An imitative word; an onomatopoetic word.